NTLA
USDIntellia Therapeutics Inc. Common Stock
वास्तविक समय मूल्य
मूल्य चार्ट
मुख्य मीट्रिक्स
बाजार मीट्रिक्स
खुलना
$8.200
उच्च
$8.445
कम
$8.060
मात्रा
9.93M
कंपनी के मौलिक सिद्धांत
बाजार पूंजीकरण
864.9M
उद्योग
जैव प्रौद्योगिकी
देश
United States
ट्रेडिंग आँकड़े
औसत मात्रा
4.19M
एक्सचेंज
NGM
मुद्रा
USD
52-सप्ताह रेंज
संबंधित समाचार
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Lowers Price Target to $54
Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics with a Buy and lowers the price target from $74 to $54.
HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $30 Price Target
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Intellia Therapeutics with a Buy and maintains $30 price target.
HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $30 Price Target
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Intellia Therapeutics with a Buy and maintains $30 price target.
Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $10 Price Target
Wedbush analyst David Nierengarten reiterates Intellia Therapeutics with a Neutral and maintains $10 price target.
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting
Deep, durable and consistent reductions in TTR were sustained at two years, following a one-time dose of nex-zClinically meaningful improvements in ATTRv-PN related outcomes observed at 24 months compared to baseline,
संबंधित स्टॉक
अपडेट रहें
मूल्य अलर्ट सेट करें, AI विश्लेषण अपडेट और वास्तविक समय बाजार समाचार प्राप्त करें।